Melatonin receptor type 1A gene linked to Alzheimer’s disease in old age

Abstract Disruption of the circadian rhythms is a frequent preclinical and clinical manifestation of Alzheimer’s disease. Furthermore, it has been suggested that shift work is a risk factor for Alzheimer’s disease. Previously, we have reported association of intolerance to shift work (job-related exhaustion in shift workers) with a variant rs12506228A, which is situated close to melatonin receptor type 1A gene (MTNR1A) and linked to MTNR1A brain expression levels. Here, we studied association of that variant with clinical and neuropathological Alzheimer’s disease in a Finnish whole-population cohort Vantaa 85+ (n = 512, participants over 85 years) and two follow-up cohorts. Rs12506228A was associated with clinical Alzheimer’s disease (p = 0.000073). Analysis of post-mortem brain tissues showed association with higher amount of neurofibrillary tangles (p = 0.0039) and amyloid beta plaques (p = 0.0041). We then followed up the associations in two independent replication samples. Replication for the association with clinical Alzheimer’s disease was detected in Kuopio 75+ (p = 0.012, n = 574), but not in the younger case-control sample (n = 651 + 669). While melatonin has been established in regulation of circadian rhythms, an independent role has been also shown for neuroprotection and specifically for anti-amyloidogenic effects. Indeed, in vitro, RNAi mediated silencing of MTNR1A increased the amyloidogenic processing of amyloid precursor protein (APP) in neurons, whereas overexpression decreased it. Our findings suggest variation close to MTNR1A as a shared genetic risk factor for intolerance to shift work and Alzheimer’s disease in old age. The genetic associations are likely to be mediated by differences in MTNR1A expression, which, in turn, modulate APP metabolism.

[1]  N. H. Rod,et al.  Shift work, long working hours, and later risk of dementia: A long-term follow-up of the Copenhagen Male Study. , 2017, Scandinavian journal of work, environment & health.

[2]  T. Åkerstedt,et al.  Shift work and cognitive aging: a longitudinal study. , 2017, Scandinavian journal of work, environment & health.

[3]  T. Åkerstedt,et al.  Midlife shift work and risk of incident dementia , 2017 .

[4]  Z. Andersen,et al.  Shift work and overall and cause-specific mortality in the Danish nurse cohort. , 2017, Scandinavian journal of work, environment & health.

[5]  T. Paunio,et al.  Common Genetic Variation Near Melatonin Receptor 1A Gene Linked to Job-Related Exhaustion in Shift Workers , 2017, Sleep.

[6]  D. Holtzman,et al.  Mechanisms linking circadian clocks, sleep, and neurodegeneration , 2016, Science.

[7]  R. Reiter,et al.  Melatonin as an antioxidant: under promises but over delivers , 2016, Journal of pineal research.

[8]  M. Dubocovich,et al.  Update on melatonin receptors: IUPHAR Review 20 , 2016, British journal of pharmacology.

[9]  L. Lind,et al.  Association between shift work history and performance on the trail making test in middle-aged and elderly humans: the EpiHealth study , 2016, Neurobiology of Aging.

[10]  J. Schneider,et al.  Relation of genomic variants for Alzheimer disease dementia to common neuropathologies , 2016, Neurology.

[11]  P. Govitrapong,et al.  Melatonin administration reverses the alteration of amyloid precursor protein-cleaving secretases expression in aged mouse hippocampus , 2016, Neuroscience Letters.

[12]  B. Vincent,et al.  Melatonin regulates the transcription of βAPP‐cleaving secretases mediated through melatonin receptors in human neuroblastoma SH‐SY5Y cells , 2015, Journal of pineal research.

[13]  J. Olcese,et al.  Prophylactic melatonin significantly reduces Alzheimer’s neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPPswe/PS1 mice , 2015, Molecular Neurodegeneration.

[14]  R. Barker,et al.  'The clocks that time us'—circadian rhythms in neurodegenerative disorders , 2014, Nature Reviews Neurology.

[15]  Simon Folkard,et al.  Chronic effects of shift work on cognition: findings from the VISAT longitudinal study , 2014, Occupational and Environmental Medicine.

[16]  Carson C Chow,et al.  Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.

[17]  Margaret A. Pericak-Vance,et al.  Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias , 2014, PLoS genetics.

[18]  Daniel J. R. Christensen,et al.  Sleep Drives Metabolite Clearance from the Adult Brain , 2013, Science.

[19]  Bernhard T. Baune,et al.  The Circadian System in Alzheimer’s Disease: Disturbances, Mechanisms, and Opportunities , 2013, Biological Psychiatry.

[20]  Janet B W Williams Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[21]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[22]  R. Reiter,et al.  A review of the molecular aspects of melatonin’s anti‐inflammatory actions: recent insights and new perspectives , 2013, Journal of pineal research.

[23]  M. Ganguli,et al.  Smoking, Death, and Alzheimer Disease: A Case of Competing Risks , 2012, Alzheimer disease and associated disorders.

[24]  O. Nosjean,et al.  Description of the constitutive activity of cloned human melatonin receptors hMT1 and hMT2 and discovery of inverse agonists , 2012, Journal of pineal research.

[25]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[26]  H. Huttunen,et al.  γ-Aminobutyric Acid Type A (GABAA) Receptor Activation Modulates Tau Phosphorylation* , 2012, The Journal of Biological Chemistry.

[27]  Sang Joon Son,et al.  Sundown Syndrome in Persons with Dementia: An Update , 2011, Psychiatry investigation.

[28]  S. Cummings,et al.  Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women , 2011, Annals of neurology.

[29]  Wei Li,et al.  The Melatonin MT1 Receptor Axis Modulates Mutant Huntingtin-Mediated Toxicity , 2011, The Journal of Neuroscience.

[30]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[31]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[32]  David Heckerman,et al.  Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study , 2010, The Lancet Neurology.

[33]  Reedik Mägi,et al.  GWAMA: software for genome-wide association meta-analysis , 2010, BMC Bioinformatics.

[34]  Seiji Nishino,et al.  Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle , 2009, Science.

[35]  J. Olcese,et al.  Protection against cognitive deficits and markers of neurodegeneration by long‐term oral administration of melatonin in a transgenic model of Alzheimer disease , 2009, Journal of pineal research.

[36]  H. Soininen,et al.  An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[37]  I. Grundke‐Iqbal,et al.  Effect of Melatonin and Melatonylvalpromide on β-amyloid and Neurofilaments in N2a Cells , 2008, Neurochemical Research.

[38]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[39]  D. Swaab,et al.  Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease , 2007, Neurobiology of Aging.

[40]  A. Kalsbeek,et al.  Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the “master clock” , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  A. Poso,et al.  The functional role of cysteines adjacent to the NRY motif of the human MT1 melatonin receptor , 2005, Journal of pineal research.

[42]  R. Sulkava,et al.  The use of psychotropics and survival in demented elderly individuals , 2005, International clinical psychopharmacology.

[43]  D. Swaab,et al.  The human pineal gland and melatonin in aging and Alzheimer's disease , 2005, Journal of pineal research.

[44]  Zheng Feng,et al.  Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease , 2004, Journal of pineal research.

[45]  R. Ravid,et al.  Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. , 2003, The Journal of clinical endocrinology and metabolism.

[46]  R. Sulkava,et al.  Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older , 2003, Journal of neurology, neurosurgery, and psychiatry.

[47]  J. Hardy,et al.  Prevalence of Alzheimer’s disease in very elderly people , 2001, Neurology.

[48]  A. Strosberg,et al.  Tight association of the human Mel(1a)-melatonin receptor and G(i): precoupling and constitutive activity. , 1999, Molecular pharmacology.

[49]  H. Soininen,et al.  Linkage disequilibrium in the 13q12 region in Finnish late onset Alzheimer's disease patients , 1999, European Journal of Human Genetics.

[50]  R. Sulkava,et al.  Genetic association of α2‐macroglobulin with Alzheimer's disease in a Finnish elderly population , 1999, Annals of neurology.

[51]  D. Lahiri Melatonin affects the metabolism of the β‐amyloid precursor protein in different cell types , 1999, Journal of Pineal Research.

[52]  Yasuo Hishikawa,et al.  Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep–waking , 1999, Biological Psychiatry.

[53]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[54]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[55]  K Kontula,et al.  Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. , 1995, The New England journal of medicine.

[56]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[57]  E. Pfeiffer A Short Portable Mental Status Questionnaire for the Assessment of Organic Brain Deficit in Elderly Patients † , 1975, Journal of the American Geriatrics Society.

[58]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[59]  R. Hu Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) , 2003 .

[60]  K. Jellinger,et al.  Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. , 2002, Neurology.